90. 網膜色素変性症
[臨床試験数:103,薬物数:158(DrugBank:42),標的遺伝子数:52,標的パスウェイ数:107

Searched query = "Retinitis pigmentosa", "Rod dystrophy", "Rod-Cone Dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-004547-77-GB
(EUCTR)
09/06/202026/02/2020Safety and Tolerability of hRPC in Retinitis PigmentosaFirst-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Subjects with Retinitis Pigmentosa (RP) Retinitis Pigmentosa
MedDRA version: 20.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: human Retinal Progenitor Cells Drug Product
Product Code: hRPC DP
INN or Proposed INN: ALLOGENEIC NEURAL RETINA-DERIVED HUMAN NEURAL RETINAL PROGENITOR CELLS EX VIVO EXPANDED
Other descriptive name: ALLOGENEIC NEURAL RETINA-DERIVED HUMAN NEURAL RETINAL PROGENITOR CELLS EX VIVO EXPANDED
ReNeuron LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
33Phase 2United States;United Kingdom
2NCT02464436
(ClinicalTrials.gov)
December 201518/5/2015Safety and Tolerability of hRPC in Retinitis PigmentosaFirst-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Patients With Retinitis Pigmentosa (RP)Retinitis PigmentosaDrug: hRPCReNeuron LimitedNULLRecruiting18 YearsN/AAll33Phase 1;Phase 2United States;United Kingdom